ArticleFrontiers in oncology2022
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Prognostic significance of KRAS G12C versus non-G12C RAS mutations in metastatic colorectal cancer: a systematic review and meta-analysis.The oncologist · 2026Pooled it
- Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review.The oncologist · 2023Pooled it
- Review
- KRAS and NRAS mutations in Nordic population-based and real-world metastatic colorectal cancer cohorts.BJC reports · 2025Article
- Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8-year study of 10 754 patients in Turkey.Molecular oncology · 2025Article
- A Narrative Review of RAS Mutations in Early-Stage Colorectal Cancer: Mechanisms and Clinical Implications.Medicina (Kaunas, Lithuania) · 2025Review
- Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c.34G>T (p.G12C) mutation.Cancer science · 2024Article
- Associations of KRAS Mutations and Clinical Characteristics of Colorectal Cancer Patients in Indonesia.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Article
- Reclassification ofTherapeutic advances in medical oncology · 2024Article
- Sotorasib with panitumumab in chemotherapy-refractory KRASNature medicine · 2024Article
- Article
- A consolidated working classification of gastric cancer for histopathologists (Review).Biomedical reports · 2023Review
- Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania.International journal of molecular sciences · 2023Article
- Clinical Characterization of Targetable Mutations (BRAF V600E and KRAS G12C) in Advanced Colorectal Cancer-A Nation-Wide Study.International journal of molecular sciences · 2023Article
- Therapeutic landscape and future direction of metastatic colorectal cancer.Nature reviews. Gastroenterology & hepatology · 2023Review
- Article
- The impact of RAS mutation on the treatment strategy of colorectal cancer.Medicine and pharmacy reports · 2023Review
- Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer.Frontiers in oncology · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 13 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
methodsPatients from three Nordic population-based cohorts and the real-life RAXO-study were combined.
resultsThe
conclusionsIn these real-life and population-based cohorts, there were no significant differences in patient characteristics and outcomes between patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.